Quality-of-life Outcomes in Men Treated for Localized Prostate Cancer

Published In: JAMA, The Journal of the American Medical Association, v. 273, Jan. 11, 1995, p. 129-135

Posted on RAND.org on December 31, 1994

by Mark Litwin, Ron D. Hays, Arlene Fink, Patricia A. Ganz, Barbara Leake, Gary E. Leach, Robert H. Brook

Read More

Access further information on this document at jama.jamanetwork.com

This article was published outside of RAND. The full text of the article can be found at the link above.

Reports on a cross-sectional analysis of HRQOL outcome measures among men treated for localized prostate cancer with either radical prostatectomy, pelvic radiation, or observation alone. An agematched comparison group without prostate cancer was also examined. Instruments included the SF-36 to measure general HRQOL, two cancer-specific instruments, and a disease-targeted instrument assessing function and bother in sexual, urinary, and bowel organ systems. Although there was no difference in general HRQOL among the three treatment groups, the prostate-targeted measures showed significant differences in function and bother. Significant differences were also seen between cancer and non-cancer patients in sexual, urinary, and bowel function and bother but not in general HRQOL. This study concludes, perhaps for the first time in patients with prostate cancer, that general measures of HRQOL are not sufficient to assess differences in outcome. There is need to develop additional disease-targeted quality-of-life measures.

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.